Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Doccole

<< Previous

Bullboard Posts

Next >>

Comment by EfTOates28on Jul 25, 2021 6:52pm

159 Views

Post# 33602473

RE:Doccole

if it was the final straw then stfu and leave all ready. We know your a sad pissed off bag holder we get it. Your down your family's saving and your pissed but posting nonsense on this wall every day is getting you no where. Go cry into a 40 of whiskey like a real man. And stop the endless whining on stock house you look and sound like a idiot

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features